Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 16, 2022

SELL
$28.92 - $41.83 $916,764 - $1.33 Million
-31,700 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $994,746 - $1.54 Million
31,700 New
31,700 $10,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.12B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.